Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Acquires 5,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $15,200.00. Following the purchase, the chief executive officer owned 635,812 shares in the company, valued at $1,932,868.48. This represents a 0.79% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Amit Kumar also recently made the following trade(s):

• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Down 1.3%

NASDAQ:ANIX traded down $0.04 on Monday, reaching $3.02. 48,739 shares of the company’s stock traded hands, compared to its average volume of 164,288. The stock has a 50-day simple moving average of $2.80 and a 200-day simple moving average of $2.90. The firm has a market cap of $102.75 million, a PE ratio of -9.74 and a beta of 0.59. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, equities analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Finally, Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.50.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIX. NewEdge Advisors LLC purchased a new stake in Anixa Biosciences during the 2nd quarter worth approximately $33,000. Cetera Investment Advisers purchased a new stake in Anixa Biosciences during the 4th quarter valued at about $35,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences in the second quarter worth about $37,000. Finally, Millennium Management LLC acquired a new stake in shares of Anixa Biosciences during the fourth quarter worth about $38,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.